{
    "clinical_study": {
        "@rank": "97376", 
        "arm_group": [
            {
                "arm_group_label": "0.05% w/w CT327 ointment", 
                "arm_group_type": "Experimental", 
                "description": "Active"
            }, 
            {
                "arm_group_label": "0.5% w/w CT327 ointment", 
                "arm_group_type": "Experimental", 
                "description": "Active"
            }, 
            {
                "arm_group_label": "vehicle", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a Phase II, multi-centre, randomised, double-blind, placebo-controlled study in male\n      and female subjects, aged \u2265 12 years with mild/moderate atopic dermatitis and at least\n      moderate pruritus. All subjects will receive BID topical applications of CT327 ointment or\n      vehicle for up to 4 weeks.\n\n      At baseline, the subjects must have atopic dermatitis, as defined by the Hanifin and Rajka\n      criteria, which involves a minimum of 5% and a maximum of 20% body surface area, an\n      Investigator Global Assessment Score of 2 or 3 (mild or moderate) and pruritus visual\n      analogue scale scores of \u2265 40mm (at least moderate).\n\n      All subjects will attend a screening visit not more than 21 days prior to Day 1. Subjects\n      will be required to return to the clinic on Days 1 (baseline visit), 4, 11, 18 and 29 (end\n      of treatment visit).  All subjects will be asked to attend for a follow-up visit 14 (\u00b13)\n      days after the last dose of study medication."
        }, 
        "brief_title": "A Study to Evaluate the Efficacy, Safety and Tolerability of CT327 in Atopic Dermatitis", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Atopic Dermatitis", 
        "condition_browse": {
            "mesh_term": [
                "Dermatitis", 
                "Dermatitis, Atopic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Male and female subjects aged \u2265 12 years.\n\n        Clinical diagnosis of atopic dermatitis (as defined by Hanifin and Rajka criteria\n        (Appendix F) at screening with:\n\n          -  IGA score of 2 or 3 (mild or moderate)\n\n          -  Score of \u2265 40mm on all screening pruritus VAS assessments (average and worst over the\n             last 24 hours and current itch)\n\n          -  A minimum of 5% and not more than 20% of the subjects' BSA affected by atopic\n             dermatitis (affected is defined as active atopic dermatitis lesions or pruritus)\n\n          -  Amenable to treatment with topical treatment\n\n          -  Stable disease for \u22651 months prior to screening\n\n        Exclusion Criteria:\n\n        Atopic dermatitis only affecting the head or scalp. Unstable or actively infected atopic\n        dermatitis. Concomitant dermatologic or medical condition(s) which may interfere with the\n        investigator's ability to evaluate the subject's response to the study drug.\n\n        Subjects who have received monoclonal antibody therapy for their atopic dermatitis in the\n        4 months prior to screening.\n\n        Subjects who have used systemic immunosuppressive drugs, corticosteroids or received PUVA\n        therapy in the 4 weeks prior to starting study treatment, or are scheduled to start these\n        treatments during the study period.\n\n        Subjects who have used topical immunomodulators (pimecrolimus, tacrolimus) within 2 weeks\n        of starting study treatment or are scheduled to start these treatments during the study\n        period.\n\n        Subjects who have used topical corticosteroids from WHO group II, III or IV, or other\n        treatments for atopic dermatitis, including wet wraps, within 2 weeks prior to starting\n        study treatment or are likely to require treatment with these medications during the study\n        period.\n\n        Subjects who are unable to abstain from using emollients from baseline (Visit 2) until the\n        end of study treatment (Visit 6).\n\n        Subjects who are using any concomitant medication(s) that, in the investigators' opinion,\n        could affect the subject's atopic dermatitis or pruritus (for example TADs, SSRI,\n        pregabalin).  Subjects using such medications may be included, at the investigators\n        discretion, if they have been stable on treatment for at least 1 month prior to the start\n        of study treatment and  no changes to these medications are planned during the study\n        period.\n\n        Subjects undergoing, or due to have, UVA, or UVB therapy in the 2 weeks prior to starting\n        study treatment or during the study period.\n\n        Planned exposure of affected areas to excessive sunlight. Subjects with a clinically\n        significant abnormal laboratory safety test and/or 12-lead ECG results at screening.\n\n        Subjects who are receiving any investigational drug or who have taken part in a clinical\n        study with an investigational drug within three months prior to the start of study\n        treatment.\n\n        Subjects with a known reaction or allergy to test drug or excipients."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "12 Years"
        }, 
        "enrollment": {
            "#text": "210", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01808157", 
            "org_study_id": "CT327-2005"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "0.05% w/w CT327 ointment", 
                    "0.5% w/w CT327 ointment"
                ], 
                "intervention_name": "CT327 ointment", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "vehicle", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "atopic dermatitis", 
            "pruritus"
        ], 
        "lastchanged_date": "November 29, 2013", 
        "location": {
            "contact": {
                "email": "jhamlin@creabilis-sa.com", 
                "last_name": "Julia Hamlin", 
                "phone": "+44 1227 833425"
            }, 
            "facility": {
                "address": {
                    "city": "Manchester, Lancashire, Midlands, Wales, Scotland", 
                    "country": "United Kingdom"
                }, 
                "name": "Synexus"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase II Randomised, Double Blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of CT327 Topical Ointment (0.05% and 0.5% w/w) Compared to Vehicle, in Subjects With Mild or Moderate Atopic Dermatitis and at Least Moderate Pruritus", 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "\u2022 To determine whether CT327 is effective in reducing pruritus in subjects with atopic dermatitis, using a pruritus visual analogue scale (VAS)", 
            "safety_issue": "No", 
            "time_frame": "4 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01808157"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "\u2022 To assess efficacy of CT327 on atopic dermatitis using the Investigator Global Assessment (IGA)", 
            "safety_issue": "No", 
            "time_frame": "4 weeks"
        }, 
        "source": "Creabilis SA", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Creabilis SA", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}